Acetylsalicylic Acid

Evidence Level: L5

Predicted Indications: 7

Acetylsalicylic Acid

Pharmacist Assessment Report

Acetylsalicylic Acid: cyclooxygenase inhibitor (NSAID, antiplatelet) → atrophoderma vermiculata

One-Sentence Summary

Acetylsalicylic acid (aspirin) is a long-established cyclooxygenase-inhibiting anti-inflammatory and antiplatelet drug marketed in Canada. The TxGNN model predicts it may be relevant to atrophoderma vermiculata, with a prediction score of 0.9959. No clinical trials and no publications were found to support this prediction, so it rests on the computational prediction alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	atrophoderma vermiculata
TxGNN Prediction Score	0.9959
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs on record: at least 20)
Number of DINs	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Aspirin is generally known to irreversibly inhibit cyclooxygenase enzymes, which reduces prostaglandin and thromboxane production. This gives it anti-inflammatory, analgesic and antiplatelet effects.

Atrophoderma vermiculata is a rare follicular atrophic skin condition. The data compiled for this report shows no clear mechanistic link between aspirin’s known pharmacology and this disease. The high score is a computational network-based prediction only. Without trials, literature or a plausible mechanism, it should be treated as a hypothesis, not as a supported repurposing opportunity.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

Health Canada records list 20 valid single-ingredient licences for aspirin products, and the records may be partial. The local data does not record dosage forms or approved-indication text for these licences, so the approved indication is not recorded in the local data. A selection of the main authorisations:

DIN	Product Name
02202352	RIVASA 80MG CROQUABLE - TAB
02363127	ENTERIC COATED DAILY LOW DOSE ASA 81 MG
02242281	ENTROPHEN
02009013	ASAPHEN
02150328	ASPIRIN REGULAR STRENGTH

Safety Considerations

Drug Interactions: 100 interactions were found in the interaction screening. Examples rated Major include acalabrutinib, acetazolamide, ketorolac, trastuzumab emtansine, ibuprofen and fondaparinux. Examples rated Moderate include abciximab, nifedipine, hydrocortisone, ethanol, alendronic acid and fluvoxamine. These mostly reflect additive bleeding or gastrointestinal risk.

Please refer to the package insert for warnings and contraindications, as label-based safety text was not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high (0.9959), but there are no clinical trials or publications for atrophoderma vermiculata and no plausible mechanistic link to aspirin. The evidence level is therefore L5, which does not justify further investment at this stage.

To proceed, the following is needed:

Mechanism of action data and a testable biological rationale linking cyclooxygenase or platelet pathways to this condition
A systematic literature search for case reports or preclinical studies in this disease
Package insert warnings and contraindications from Health Canada for a safety review
Dermatology expert review of whether the prediction is clinically meaningful
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.